Efficacy and Safety of DCAG Regimen vs. Standard Therapy for TP53-Mutant Acute Myeloid Leukemia
For patients with acute myeloid leukemia (AML) who carry a TP53 mutation—an alteration in a critical gene that normally prevents cancer growth—standard chemotherapy often fails, leading to devastatingly poor survival rates. But a 2021 study from Chinese researchers suggests a combination regimen called DCAG (decitabine + low-dose cytarabine + aclarubicin + granulocyte colony-stimulating factor, or G-CSF) may offer new hope, particularly for those with the most aggressive forms of the disease.
Led by a team from the First Affiliated Hospital of Nanjing Medical University and the Affiliated Yixing Hospital of Jiangsu University, the study analyzed 33 AML patients with TP53 mutations treated between 2011 and 2018. Twenty-one received the DCAG regimen, while 12 underwent standard induction therapy (either idarubicin + cytarabine or high-dose cytarabine + fludarabine). All patients were diagnosed using World Health Organization (WHO) 2016 criteria, and TP53 mutations were confirmed via targeted gene sequencing or Sanger sequencing.
How the Study Worked
Researchers tracked patients until May 2019, using National Comprehensive Cancer Network (NCCN) 2020 guidelines to measure treatment responses (complete remission, or CR; partial remission, or PR; and overall response rate, or ORR). Safety was assessed using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, with a focus on side effects like low blood counts (neutropenia, thrombocytopenia) and infections.
Key Results: DCAG Outperforms Standard Therapy for High-Risk Patients
The DCAG regimen showed meaningful benefits—especially for patients with “poor-risk karyotypes” (abnormal chromosome structures that make AML harder to treat):
- Overall Response: 60% of DCAG patients achieved CR (no detectable leukemia) vs. 30% in the standard group. DCAG’s ORR (CR + PR) was 70% vs. 30% for standard therapy.
- Poor-Risk Karyotypes: For patients with this high-risk feature, DCAG delivered a 56% CR rate and a median survival of 7.8 months. Standard therapy? 0% CR and just 3 months of median survival.
- Mutation Clearance: Three of five DCAG patients retested after one course had no detectable TP53 mutation (measured by variant allele frequency, VAF). Five DCAG patients also achieved undetectable minimal residual disease (MRD)—a strong marker of long-term remission.
Safety: Manageable Side Effects
Both regimens caused similar side effects, with low blood counts and infections being the most common. One DCAG patient and two standard therapy patients died early from infections during treatment, but most adverse events were controlled with supportive care. The infection rate was 85.7% in the DCAG group vs. 100% in the standard group—no statistically significant difference.
Why DCAG Works
DCAG’s success comes from its unique mechanism:
- Decitabine: A DNA methyltransferase inhibitor that reactivates silenced tumor suppressor genes. Unlike standard chemo, it doesn’t rely on the broken TP53 pathway to kill cancer cells.
- G-CSF: Pushes leukemia cells from the dormant G0/G1 phase into the active S phase, where chemotherapy drugs are more effective.
- Synergy: Decitabine enhances the cytotoxicity of cytarabine, creating a one-two punch against leukemia cells.
What This Means for Patients
While the study is small (33 patients), it highlights DCAG as a promising option for TP53-mutant AML—especially for older patients (DCAG patients had a median age of 67 vs. 51 for standard therapy) or those with myelodysplasia-related AML (AML-MRC), a subtype linked to worse outcomes. However, researchers stress that larger, prospective studies are needed to confirm these findings.
The study was published in the Chinese Medical Journal in 2021 by Si-Si Chen, Qian Sun, Lan Cao, Wen-Zhong Wu, Yue Xie, Chun Qiao, Jian-Yong Li, Si-Xuan Qian, and Ming Hong. You can access the original research at doi.org/10.1097/CM9.0000000000001316
Was this helpful?
0 / 0